Publication date: Jul 10, 2019
An experimental treatment known as OB-002, that works to block an inflammatory molecule in the brain, prevented the development of lesions there after an early-in-life viral infection in a mouse model of multiple sclerosis (MS). A research team from Switzerland and Germany found that viral infection in the brains of mice early in life, but not at a later age, worsened those MS symptoms evident in a brain, like lesions, at sites where the virus had resided but was cleared. -Early-life infection of mouse brains imprinted a chronic inflammatory signature that consisted of brain-resident memory T-cells expressing the chemokine (C-C motif) ligand 5 (CCL5),” the researchers wrote. Overall, the results showed that -transient brain viral infection early in life worsened lesion development and symptoms in a mouse model of autoimmune disease,” and that -autoimmune lesions were spatially associated with areas of previous viral infection in mice,” the researchers wrote.
- Orion Biotechnology’s CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis
- Is multiple sclerosis linked to childhood viral infections?
- Viral Infections In Childhood Might Trigger Multiple Sclerosis
- How childhood viral infections may later drive multiple sclerosis
- miR-142-3p as Potential Biomarker of Synaptopathy in MS